A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Quotient Sciences Sea View, Miami, Florida